Member Info for trillsg

Doesn't matter bud. What does is we were both impressed.

If this thread from Gerard doesn't give you confidence in what the future holds nothing will.
https://twitter.com/gjbrandon/status/1401487006962786308

My pleasure Phil. Good to see a new face on the BB. They know what they’re doing and it’s going to eventually be huge.

Was, "ready to ship" a clue?
https://twitter.com/gjbrandon/status/1400421884710301701?s=20

The expertise and experts behind the manufacture of our core technology, scaling up and getting product ready to ship!

That's the Mass Spectrometry unit that will analyse the MicrotoxBT results.

The tests are probably taking longer than we'd like as detecting Covid is only a small part of it. The tie up with Microsaic was to miniaturise the mass spectrometry to enable it to be used by the police to detect drug users. Also 40 other medical diseases to be used by GP's . What they are testing it for are there in the document. MicrotoxBT will be used worldwide even when the pandemic is long forgotten about.

Point-of-care diagnostics in the human health industry

Disruption in the human health care industry is driven by the demand for point-of-care diagnostics and real-time monitoring systems. Growth in the healthcare market is projected at a CAGR of 38.05% between 2020-2028, propelled by AI and portable digital health diagnostics.

That’s why Microsaic is collaborating with DeepVerge to accelerate the development of the MicrotoxBT breathalyser. This ground-breaking device combines miniaturised mass spectrometry with DeepVerge’s AI data analytics to detect Spike Proteins of the COVID-19 virus, SARS-CoV-2, on a person’s breath. Resulting in fast, reliable, and efficient test results of the population at the point-of-need.

This combination platform opens up opportunities that would enable GP clinics to refer serious conditions, by using biomarker binding agents capable of detecting up to 40 diseases on the human breath, including:

Cancer
Neurodegenerative conditions
Respiratory illnesses
Metabolic conditions
Deployable MS instrumentation would eliminate unnecessary doctor-to-hospital referrals and over-prescription of antibiotics, resulting in significantly increased productivity and reduced healthcare costs.

Appreciate the time and effort you put in to this as I imagine many other investors do too.

3 of the 7 members of the EcowaterOS consortium are owned by DV, Cellulac, Rinocloud and Modernwater so you'd hope we'd get a decent slice. Avacta and Aptamer Group aren't amongst them as I guess they'll make their money from the sales of their slides to us.

Very clever Bulsara. You see Muggins some of the clever ones have stayed.

Cheers NU. I only passed C GCSE's, Englandish wasn't two of them either.

"If a tree falls on a dog in a forest and no one is around to hear it, does it make a sound?"

"Modern Water Microtox used at 8 of the last 9 Summer Olympics" I know this will be a stupid question but will ask it anyway.
Every 4 years, 9 x 4 =36 but MW only been going for 30?

Could be the dreaded Muggins Mutation! Twice as deadly as trufflehound and Watercrisis. Luckily if you promise to sell your DV shares it goes away.

I remembered this from a previous company I was invested in. Hopefully they'd qualify and recoup much of BT and PD's development costs.

Small and medium sized enterprises (SME) R&D Relief
You can claim SME R&D relief if you’re a SME with:

less than 500 staff
a turnover of under 100 million euros or a balance sheet total under 86 million euros
You may need to include linked companies and partnerships when you work out if you’re a SME.

https://www.gov.uk/guidance/corporation-tax-research-and-development-rd-relief#history

SME R&D relief allows companies to:

deduct an extra 130% of their qualifying costs from their yearly profit, as well as the normal 100% deduction, to make a total 230% deduction
claim a tax credit if the company is loss making, worth up to 14.5% of the surrenderable loss

https://static1.squarespace.com/static/5fafd265d2fcd81f31aec996/t/6093e2b4af366c4aeffea0bd/1620304574684/PulmoBioMed+Coronavirus+-+Public+06.05.2021.pdf

Safely: Kill the virus.
More reliably: Larger sample than nasal swabs.
Simply: With no skills needed: just breathe out.
Using mass screening: by mass production of plastic.
Where patients are: using any point of need testing system.
With current gold standard tests:
e.g. Any laboratory RT-PCR instrument
e.g. Abbott ID NOW®: 5 min test or LFT/LFD
e.g. DeepVerge MicroTox BT: 4 sec test.

Prototype: Clinical Pilot Update. Clinical data as of 5/05/21
NO FALSE POSITIVES:
§ COVID19 patients (n=12).
§ Nasal swab negative.
§ Week 2-3 of symptoms, known
nasal –ve period.
§ Antivirals / hydroxychloroquine.
§ (dyspnoea) 25-30 breaths/min.
§ 5-20 min sampling.
§ In COVID19 wards.
§ Blinded analysis.
N=60 study ongoing
§ Actively recruiting.
§ Must be in 0-5 days from
symptom onset
§ Must be nasal positive by RTPCR
§ N=18 completed
§ Interim data release: n=30
§ Limited attendance at week 1 of
symptoms slows recruitment.

No idea what the above data means, worth looking at acknowledgments, bottom of page.

Cheers bud, appreciate that.

Happens every year to every stock whilst school holidays are on. Looks to me like TP know this and are holding off so they don’t trash the sp, or they’re done. They don’t have to sell them all, maybe happy with their profits and holding the rest for bigger ones. Pleased no major news has been announced whilst few are watching. It’s coming.

Yeah cheers, it'll be priced in and most getting out whilst you ramp. Thanks anyway.

Indeed Muggins, I will cry myself to sleep tonight. Thanks for your most informative post.

It will be sad to see you go Muggins. As you never see an end to this misery I guess you'll be selling. I wish you look in your future investments.

T.Rat, their recommendation, reference Q12, would suggest that some of their guidance would not be applicable to MicrotoxBt so as to fast track it.